In HER2-positive breast cancer cells, PIK3CA mutations and PTEN loss cause constitutive activation of PI3K/AKT/mTOR signals leading to oncogenesis as well as anti-HER2 resistance [10, 11]. The gene discussed is ERBB2; the disease is breast carcinoma.